BRIEF-Sqz Biotechnologies Announces Confirmed Complete Response In Hpv16+ Solid Tumor Patient In The Lowest-Dose Cohort Of The Sqz-Aac-Hpv-101 Clinical Trial

Reuters2023-03-23

March 22 (Reuters) - SQZ Biotechnologies Co :

* SQZ BIOTECHNOLOGIES ANNOUNCES CONFIRMED COMPLETE RESPONSE IN HPV16+ SOLID TUMOR PATIENT IN THE LOWEST-DOSE COHORT OF THE SQZ-AAC-HPV-101 CLINICAL TRIAL

* SQZ BIOTECHNOLOGIES CO - A CONFIRMED COMPLETE RESPONSE WAS OBSERVED IN FIRST PATIENT IN LOWEST-DOSE COHORT OF PHASE 1 SQZ-AAC-HPV-101 CLINICAL TRIAL

* SQZ BIOTECHNOLOGIES CO - AFTER REVIEW AND RECOMMENDATION BY STUDY SAFETY COMMITTEE, COMPANY IS ADVANCING SQZ-AAC-HPV-101 TRIAL TO HIGHEST-DOSE COHORT

* SQZ BIOTECHNOLOGIES CO - ANTICIPATE INITIAL CLINICAL DATA FROM HIGHEST-DOSE COHORT IN Q4 OF 2023

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2321612913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-03-23 04:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2321612913","market":"us","top_or_hot":-1,"title":"BRIEF-Sqz Biotechnologies Announces Confirmed Complete Response In Hpv16+ Solid Tumor Patient In The Lowest-Dose Cohort Of The Sqz-Aac-Hpv-101 Clinical Trial","media":"Reuters","content":"<html><body><p>March 22 (Reuters) - SQZ Biotechnologies Co   :</p><p>   * SQZ BIOTECHNOLOGIES ANNOUNCES CONFIRMED COMPLETE RESPONSE IN HPV16+ SOLID TUMOR PATIENT IN THE LOWEST-DOSE <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF THE SQZ-AAC-HPV-101 CLINICAL TRIAL</p><p>   * SQZ BIOTECHNOLOGIES CO - A CONFIRMED COMPLETE RESPONSE WAS OBSERVED IN FIRST PATIENT IN LOWEST-DOSE COHORT OF PHASE 1 SQZ-AAC-HPV-101 CLINICAL TRIAL</p><p>   * SQZ BIOTECHNOLOGIES CO - AFTER REVIEW AND RECOMMENDATION BY STUDY SAFETY COMMITTEE, COMPANY IS ADVANCING SQZ-AAC-HPV-101 TRIAL TO HIGHEST-DOSE COHORT</p><p>   * SQZ BIOTECHNOLOGIES CO - ANTICIPATE INITIAL CLINICAL DATA FROM HIGHEST-DOSE COHORT IN Q4 OF 2023</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sqz Biotechnologies Announces Confirmed Complete Response In Hpv16+ Solid Tumor Patient In The Lowest-Dose Cohort Of The Sqz-Aac-Hpv-101 Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sqz Biotechnologies Announces Confirmed Complete Response In Hpv16+ Solid Tumor Patient In The Lowest-Dose Cohort Of The Sqz-Aac-Hpv-101 Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-23 04:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 22 (Reuters) - SQZ Biotechnologies Co   :   * SQZ BIOTECHNOLOGIES ANNOUNCES CONFIRMED COMPLETE RESPONSE IN HPV16+ SOLID TUMOR PATIENT IN THE LOWEST-DOSE COHORT OF THE SQZ-AAC-HPV-101 CLINICAL ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2321612913","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2321612913","pubTimestamp":1679518271,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 22 (Reuters) - SQZ Biotechnologies Co   :   * SQZ BIOTECHNOLOGIES ANNOUNCES CONFIRMED COMPLETE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4139":"生物科技"},"translate_title":"简介-Sqz生物技术公司宣布，在Sqz-Aac-Hpv-101临床试验的最低剂量队列中，HPV-16+实体瘤患者已确认完全缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SQZ":0.9},"content_text":"March 22 (Reuters) - SQZ Biotechnologies Co   :   * SQZ BIOTECHNOLOGIES ANNOUNCES CONFIRMED COMPLETE RESPONSE IN HPV16+ SOLID TUMOR PATIENT IN THE LOWEST-DOSE COHORT OF THE SQZ-AAC-HPV-101 CLINICAL TRIAL   * SQZ BIOTECHNOLOGIES CO - A CONFIRMED COMPLETE RESPONSE WAS OBSERVED IN FIRST PATIENT IN LOWEST-DOSE COHORT OF PHASE 1 SQZ-AAC-HPV-101 CLINICAL TRIAL   * SQZ BIOTECHNOLOGIES CO - AFTER REVIEW AND RECOMMENDATION BY STUDY SAFETY COMMITTEE, COMPANY IS ADVANCING SQZ-AAC-HPV-101 TRIAL TO HIGHEST-DOSE COHORT   * SQZ BIOTECHNOLOGIES CO - ANTICIPATE INITIAL CLINICAL DATA FROM HIGHEST-DOSE COHORT IN Q4 OF 2023Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2321612913"}